| pubmed-article:16904316 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16904316 | lifeskim:mentions | umls-concept:C0243077 | lld:lifeskim |
| pubmed-article:16904316 | pubmed:issue | 19 | lld:pubmed |
| pubmed-article:16904316 | pubmed:dateCreated | 2006-8-25 | lld:pubmed |
| pubmed-article:16904316 | pubmed:abstractText | We have developed efficient synthesis of morpholinone-based cyclic mimetics of the P1/P2 portion of the HIV-1 protease inhibitor Amprenavir. This effort led to discovery of allyl- and spiro-cyclopropyl-P2-substituted inhibitors 17 and 31, both 500 times more potent than the parent inhibitor 1. These results support morpholinones as novel mimetics of the P1/P2 portion of Amprenavir and potentially of other HIV-protease inhibitors, and thus provide a novel medicinal chemistry template for optimization toward more potent and drug-like inhibitors. | lld:pubmed |
| pubmed-article:16904316 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16904316 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16904316 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16904316 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16904316 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16904316 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16904316 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16904316 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16904316 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16904316 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16904316 | pubmed:month | Oct | lld:pubmed |
| pubmed-article:16904316 | pubmed:issn | 0960-894X | lld:pubmed |
| pubmed-article:16904316 | pubmed:author | pubmed-author:KazmierskiWie... | lld:pubmed |
| pubmed-article:16904316 | pubmed:author | pubmed-author:FurfineEricE | lld:pubmed |
| pubmed-article:16904316 | pubmed:author | pubmed-author:SpaltensteinA... | lld:pubmed |
| pubmed-article:16904316 | pubmed:author | pubmed-author:WrightLois... | lld:pubmed |
| pubmed-article:16904316 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16904316 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:16904316 | pubmed:volume | 16 | lld:pubmed |
| pubmed-article:16904316 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16904316 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16904316 | pubmed:pagination | 5226-30 | lld:pubmed |
| pubmed-article:16904316 | pubmed:meshHeading | pubmed-meshheading:16904316... | lld:pubmed |
| pubmed-article:16904316 | pubmed:meshHeading | pubmed-meshheading:16904316... | lld:pubmed |
| pubmed-article:16904316 | pubmed:meshHeading | pubmed-meshheading:16904316... | lld:pubmed |
| pubmed-article:16904316 | pubmed:meshHeading | pubmed-meshheading:16904316... | lld:pubmed |
| pubmed-article:16904316 | pubmed:meshHeading | pubmed-meshheading:16904316... | lld:pubmed |
| pubmed-article:16904316 | pubmed:meshHeading | pubmed-meshheading:16904316... | lld:pubmed |
| pubmed-article:16904316 | pubmed:meshHeading | pubmed-meshheading:16904316... | lld:pubmed |
| pubmed-article:16904316 | pubmed:meshHeading | pubmed-meshheading:16904316... | lld:pubmed |
| pubmed-article:16904316 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16904316 | pubmed:articleTitle | New, potent P1/P2-morpholinone-based HIV-protease inhibitors. | lld:pubmed |
| pubmed-article:16904316 | pubmed:affiliation | GlaxoSmithKline, MV CEDD, Five Moore Drive, Research Triangle Park, NC 27709, USA. wieslaw.m.kazmierski@gsk.com | lld:pubmed |
| pubmed-article:16904316 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:16904316 | lld:chembl |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16904316 | lld:pubmed |
